# Autolus Therapeutics to Participate in Upcoming Investor Conference
Canonical URL: https://biopharmsignal.com/news/AUTL/autolus-therapeutics-to-participate-in-upcoming-investor-conference-ec70e012
Ticker: AUTL
Company: Autolus Therapeutics plc
Source: Autolus Therapeutics plc
Published: 2026-06-25 11:00 EST
## Summary

Autolus will present at the H.C. Wainwright Cell Therapy Conference on June 30, 2026....

## Article Body
Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announced that the Company will participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference.

Autolus Chief Executive Officer Dr. Christian Itin will present in a Fireside Chat on Tuesday, June 30, 2026 at 9:00am EDT / 14:00pm BST.

A webcast of the fireside chat will be available on the “Events” page in the “Investor Relations & Media” section of the Company’s website at https://www.autolus.com/investor-relations-media/events/. A replay of the webcast will be archived on the Company’s website for 90 days following the presentation.

About Autolus Therapeutics plc Autolus Therapeutics plc (Nasdaq: AUTL) is a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation T cell therapies and candidates for the treatment of cancer and autoimmune disease. Using a broad suite of proprietary and modular T cell programming technologies, Autolus is engineering precisely targeted and controlled T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and eliminate these cells. Autolus has a marketed therapy, AUCATZYL ® , and a pipeline of product candidates in development for the treatment of hematological malignancies, solid tumors and autoimmune diseases. For more information, please visit www.autolus.com .

Contact:

Amanda Cray +1 617-967-0207 a.cray@autolus.com
## Recent Company News
- 2026-07-01 20:05 EST — [Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/AUTL/autolus-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635--c43a8fbe) — Source: Autolus Therapeutics plc
- 2026-06-25 11:00 EST — [Autolus Therapeutics to Participate in Upcoming Investor Conference](https://biopharmsignal.com/news/AUTL/autolus-therapeutics-to-participate-in-upcoming-investor-conference-ec70e012) — Source: Autolus Therapeutics plc
- 2026-06-12 08:00 EST — [Autolus Therapeutics Receives Prix Galien UK Award](https://biopharmsignal.com/news/AUTL/autolus-therapeutics-receives-prix-galien-uk-award-395b0660) — Source: Autolus Therapeutics plc
- 2026-05-27 11:00 EST — [Autolus Therapeutics to Participate in Upcoming Investor Conferences](https://biopharmsignal.com/news/AUTL/autolus-therapeutics-to-participate-in-upcoming-investor-conferences-1fafa41c) — Source: Autolus Therapeutics plc
- 2026-05-21 21:10 EST — [Autolus Therapeutics to Present Clinical Data Update at the American Society of Clinical Oncology Annual Meeting 2026](https://biopharmsignal.com/news/AUTL/autolus-therapeutics-to-present-clinical-data-update-at-the-american-society-of--55624eac) — Source: Autolus Therapeutics plc
## Related News
- 2026-07-28 20:15 EST — BDX — [BD Board Declares Dividend](https://biopharmsignal.com/news/BDX/bd-board-declares-dividend-ea66eb4a)
- 2026-07-28 13:00 EST — ENLV — [Enlivex Announces $400,000,000 Private Placement](https://biopharmsignal.com/news/ENLV/enlivex-announces-400-000-000-private-placement-20e71a7a)
- 2026-07-28 12:30 EST — XRAY — [Dentsply Sirona Advances Commercial Growth Strategy in Canada Through Expanded Medline Sinclair Relationship](https://biopharmsignal.com/news/XRAY/dentsply-sirona-advances-commercial-growth-strategy-in-canada-through-expanded-m-e2440bb2)
- 2026-07-28 12:30 EST — RLMD — [Relmada Therapeutics Appoints Uro-Oncology Leader Bipin Dalmia as Chief Business Officer](https://biopharmsignal.com/news/RLMD/relmada-therapeutics-appoints-uro-oncology-leader-bipin-dalmia-as-chief-business-5c4d7b11)
- 2026-07-28 12:05 EST — RIGL — [Rigel Announces Conference Call and Webcast to Report Second Quarter 2026 Financial Results](https://biopharmsignal.com/news/RIGL/rigel-announces-conference-call-and-webcast-to-report-second-quarter-2026-financ-5b987d7a)